| . | N . | %/mean . | SD . | Median . |
|---|---|---|---|---|
| Age | 141 | 45.1 | 14.2 | 45.0 |
| Age at Diagnosis | 141 | 33.9 | 12.8 | 32.0 |
| Sex | ||||
| Male | 81 | 57.4 | ||
| Female | 60 | 42.6 | ||
| Smoking Status | ||||
| Non smoker | 52 | 36.9 | ||
| Former smoker | 61 | 43.2 | ||
| Active smoker | 28 | 19.9 | ||
| Montreal Classification | ||||
| Age | ||||
| A1 <16 | 8 | 5.7 | ||
| A2 (17-40) | 87 | 61.7 | ||
| A3 (>40) | 28 | 32.6 | ||
| Location | ||||
| L1: ileal | 88 | 62.4 | ||
| L2: colonic | 3 | 2.1 | ||
| L3: ileocolonic | 50 | 35.5 | ||
| L4: isolated upper GI | 0 | 0.0 | ||
| Behavior | ||||
| B1: nonstricturing, nonpenetrating | 19 | 13.5 | ||
| B2: stricturing | 77 | 54.6 | ||
| B3: penetrating | 45 | 31.9 | ||
| Preoperative History | ||||
| Topical steroids | 45 | 31.9 | ||
| Systemic steroids | 66 | 46.8 | ||
| Thiopurine | 38 | 27.0 | ||
| Methotrexate | 6 | 4.3 | ||
| Infliximab | 13 | 9.2 | ||
| Adalimumab | 31 | 22.0 | ||
| Vedolizumab | 3 | 2.1 | ||
| Ustekinumab | 4 | 2.8 | ||
| Familiarity for IBD | ||||
| Positive | 17 | 12.1 | ||
| Perianal Disease | 24 | 17.0 | ||
| Upper GI Involvement | 5 | 3.5 | ||
| Concomitant Rheumatologic Disease | ||||
| None | 131 | 93.0 | ||
| Spondylarthritis | 2 | 1.4 | ||
| Enteropathic arthritis | 2 | 1.4 | ||
| Ankylosing spondylitis | 2 | 1.4 | ||
| Sacroileitis | 4 | 2.8 | ||
| . | N . | %/mean . | SD . | Median . |
|---|---|---|---|---|
| Age | 141 | 45.1 | 14.2 | 45.0 |
| Age at Diagnosis | 141 | 33.9 | 12.8 | 32.0 |
| Sex | ||||
| Male | 81 | 57.4 | ||
| Female | 60 | 42.6 | ||
| Smoking Status | ||||
| Non smoker | 52 | 36.9 | ||
| Former smoker | 61 | 43.2 | ||
| Active smoker | 28 | 19.9 | ||
| Montreal Classification | ||||
| Age | ||||
| A1 <16 | 8 | 5.7 | ||
| A2 (17-40) | 87 | 61.7 | ||
| A3 (>40) | 28 | 32.6 | ||
| Location | ||||
| L1: ileal | 88 | 62.4 | ||
| L2: colonic | 3 | 2.1 | ||
| L3: ileocolonic | 50 | 35.5 | ||
| L4: isolated upper GI | 0 | 0.0 | ||
| Behavior | ||||
| B1: nonstricturing, nonpenetrating | 19 | 13.5 | ||
| B2: stricturing | 77 | 54.6 | ||
| B3: penetrating | 45 | 31.9 | ||
| Preoperative History | ||||
| Topical steroids | 45 | 31.9 | ||
| Systemic steroids | 66 | 46.8 | ||
| Thiopurine | 38 | 27.0 | ||
| Methotrexate | 6 | 4.3 | ||
| Infliximab | 13 | 9.2 | ||
| Adalimumab | 31 | 22.0 | ||
| Vedolizumab | 3 | 2.1 | ||
| Ustekinumab | 4 | 2.8 | ||
| Familiarity for IBD | ||||
| Positive | 17 | 12.1 | ||
| Perianal Disease | 24 | 17.0 | ||
| Upper GI Involvement | 5 | 3.5 | ||
| Concomitant Rheumatologic Disease | ||||
| None | 131 | 93.0 | ||
| Spondylarthritis | 2 | 1.4 | ||
| Enteropathic arthritis | 2 | 1.4 | ||
| Ankylosing spondylitis | 2 | 1.4 | ||
| Sacroileitis | 4 | 2.8 | ||
Abbreviations: SD, standard deviation, IBD, inflammatory bowel disease, GI, gastrointestinal.
| . | N . | %/mean . | SD . | Median . |
|---|---|---|---|---|
| Age | 141 | 45.1 | 14.2 | 45.0 |
| Age at Diagnosis | 141 | 33.9 | 12.8 | 32.0 |
| Sex | ||||
| Male | 81 | 57.4 | ||
| Female | 60 | 42.6 | ||
| Smoking Status | ||||
| Non smoker | 52 | 36.9 | ||
| Former smoker | 61 | 43.2 | ||
| Active smoker | 28 | 19.9 | ||
| Montreal Classification | ||||
| Age | ||||
| A1 <16 | 8 | 5.7 | ||
| A2 (17-40) | 87 | 61.7 | ||
| A3 (>40) | 28 | 32.6 | ||
| Location | ||||
| L1: ileal | 88 | 62.4 | ||
| L2: colonic | 3 | 2.1 | ||
| L3: ileocolonic | 50 | 35.5 | ||
| L4: isolated upper GI | 0 | 0.0 | ||
| Behavior | ||||
| B1: nonstricturing, nonpenetrating | 19 | 13.5 | ||
| B2: stricturing | 77 | 54.6 | ||
| B3: penetrating | 45 | 31.9 | ||
| Preoperative History | ||||
| Topical steroids | 45 | 31.9 | ||
| Systemic steroids | 66 | 46.8 | ||
| Thiopurine | 38 | 27.0 | ||
| Methotrexate | 6 | 4.3 | ||
| Infliximab | 13 | 9.2 | ||
| Adalimumab | 31 | 22.0 | ||
| Vedolizumab | 3 | 2.1 | ||
| Ustekinumab | 4 | 2.8 | ||
| Familiarity for IBD | ||||
| Positive | 17 | 12.1 | ||
| Perianal Disease | 24 | 17.0 | ||
| Upper GI Involvement | 5 | 3.5 | ||
| Concomitant Rheumatologic Disease | ||||
| None | 131 | 93.0 | ||
| Spondylarthritis | 2 | 1.4 | ||
| Enteropathic arthritis | 2 | 1.4 | ||
| Ankylosing spondylitis | 2 | 1.4 | ||
| Sacroileitis | 4 | 2.8 | ||
| . | N . | %/mean . | SD . | Median . |
|---|---|---|---|---|
| Age | 141 | 45.1 | 14.2 | 45.0 |
| Age at Diagnosis | 141 | 33.9 | 12.8 | 32.0 |
| Sex | ||||
| Male | 81 | 57.4 | ||
| Female | 60 | 42.6 | ||
| Smoking Status | ||||
| Non smoker | 52 | 36.9 | ||
| Former smoker | 61 | 43.2 | ||
| Active smoker | 28 | 19.9 | ||
| Montreal Classification | ||||
| Age | ||||
| A1 <16 | 8 | 5.7 | ||
| A2 (17-40) | 87 | 61.7 | ||
| A3 (>40) | 28 | 32.6 | ||
| Location | ||||
| L1: ileal | 88 | 62.4 | ||
| L2: colonic | 3 | 2.1 | ||
| L3: ileocolonic | 50 | 35.5 | ||
| L4: isolated upper GI | 0 | 0.0 | ||
| Behavior | ||||
| B1: nonstricturing, nonpenetrating | 19 | 13.5 | ||
| B2: stricturing | 77 | 54.6 | ||
| B3: penetrating | 45 | 31.9 | ||
| Preoperative History | ||||
| Topical steroids | 45 | 31.9 | ||
| Systemic steroids | 66 | 46.8 | ||
| Thiopurine | 38 | 27.0 | ||
| Methotrexate | 6 | 4.3 | ||
| Infliximab | 13 | 9.2 | ||
| Adalimumab | 31 | 22.0 | ||
| Vedolizumab | 3 | 2.1 | ||
| Ustekinumab | 4 | 2.8 | ||
| Familiarity for IBD | ||||
| Positive | 17 | 12.1 | ||
| Perianal Disease | 24 | 17.0 | ||
| Upper GI Involvement | 5 | 3.5 | ||
| Concomitant Rheumatologic Disease | ||||
| None | 131 | 93.0 | ||
| Spondylarthritis | 2 | 1.4 | ||
| Enteropathic arthritis | 2 | 1.4 | ||
| Ankylosing spondylitis | 2 | 1.4 | ||
| Sacroileitis | 4 | 2.8 | ||
Abbreviations: SD, standard deviation, IBD, inflammatory bowel disease, GI, gastrointestinal.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
